Our valuable data support the use of CEACAM5 as a dynamic adverse prognostic CTC biomarker in patients with metastatic CRC; the findings should be interpreted with caution due to the limitation of the study (retrospective analysis, non-randomized cases, different treatment regimens, etc.). Here, CEACAM5 is linked to colorectal carcinoma.